Science will once again take over the bars of Cantabria this May with the Pint of Science festival, the international event that brings cutting-edge research closer to the general public in a relaxed and accessible environment. And this year, several researchers from IDIVAL will be part of the program, sharing their knowledge and projects in different venues across Santander, Torrelavega, and Castro Urdiales.

For three consecutive evenings —May 19, 20, and 21— researchers from fields such as health economics, nanomedicine, psychiatry, and clinical microbiology will take to the stage in local bars to talk about science in a friendly and accessible way for all audiences.

Here’s the lineup of talks featuring IDIVAL researchers:

Monday, May 19

• Ana Peleteiro and Marta Díaz (Cohorte Cantabria) at Bar Rvbicón, Santander: How to research with 50,000 people in Cantabria?

• Carlos Armiñanzas (Infectious Diseases and Clinical Microbiology group) at Coctelería La Solía, Santander: When everything can turn into a comic book

• Olga de Cos (Health Economics group) at New Century, Torrelavega: Is the village fading away? Check the pyramid

Tuesday, May 20

• Paloma Fuentes (Psychiatry and Mental Health group) at Bar Pistones&Bielas, Castro Urdiales: Neurodrama: The brain behind your emotions

• Manuela Contreras (Nursing group) at Bar Pistones&Bielas, Castro Urdiales: Talking to children about birth and death: Let’s untangle it
  

  • In addition, María José Marín, Coordinator of Technological Services and Scientific Director of the Valdecilla Biobank, will be moderating the talks on this day in Castro Urdiales.

Wednesday, May 21

• Mónica López (Nanomedicine group) at Bar Rvbicón, Santander: Cancer target: Nanorobots on the attack

• Claudia Ovejas (Psychiatry and Mental Health group) at New Century, Torrelavega: Reality hacked: Drugs and psychosis

• Marina Barreda and Daniel Coca (Health Economics group) at New Century, Torrelavega: Made-to-order health: Economics without a prescription!

All talks will start at 7:00 p.m., with free admission until the venue reaches capacity.

Science in the bars: learning in a different way

The Pint of Science festival is held simultaneously in bars around the world and offers a unique, relaxed, and participative way to experience science. In Cantabria, the event returns to Santander, Torrelavega, and Castro Urdiales, with talks on topics as varied as cancer, mental health, rural demography, and health economics.

At IDIVAL, we would like to congratulate all our researchers for joining this initiative, which helps to promote scientific knowledge and inspire future research vocations in society.

Check the full program and venues at Pint of Science Spain

The Marqués de Valdecilla Research Institute (IDIVAL) has secured funding to lead a European project aimed at improving healthcare and social care services in rural and hard-to-reach areas. This initiative, known as the Intelligent Digital Twin (IDT)-SAM, has a budget of 1.96 million euros, of which 1.47 million come from FEDER funds.

The project, which will be piloted locally in the municipality of Penagos, involves partners from Spain, France, and Portugal, and is part of the Interreg Sudoe cross-border cooperation programme, which seeks to provide common solutions to the territories of southwest Europe.

A strategic leadership for Cantabria

For IDIVAL, leading this project represents not only important recognition of its management capacity and international standing but also an opportunity to position Cantabria as a benchmark in integrated care for vulnerable populations in rural settings.

In this regard, the rural health centre in Penagos, coordinated by Dr. Talledo — a primary care physician from the Cantabrian Health Service (SCS), will serve as one of the pilot sites where the SAM model will be deployed to enhance the quality of life for vulnerable individuals.

A diverse and specialised consortium

The project brings together 19 partners, including beneficiaries and associated entities, from the fields of health research, public administration, the scientific system, NGOs, and social care organisations. Among them are leading centres such as the University of Cantabria, the Aragon Health Research Institute (IISA), IBIMA-FIMABIS in Andalusia, and the Portuguese organisation AIDFM.

In addition, public administrations at regional and municipal levels are participating, such as the Regional Ministry of Health of the Government of Cantabria, the Communauté de communes du Pays de Nay (France), and the Câmara Municipal de Pinhel (Portugal), among others.

IDIVAL: a reference in health and social care innovation

The Marqués de Valdecilla Research Institute is an accredited centre by the Carlos III Health Institute and has a strong track record in biomedical and social care innovation. Thanks to its agreement with the Regional Ministry of Health of the Government of Cantabria, IDIVAL is able to implement projects through the Cantabrian Health Service, acting as a healthcare R&D executing agency in the region.

The approval of this project further strengthens its position in the transformation of the health and social care model in rural settings, combining care, research, and applied innovation.

Photo caption: María Luisa Sámano, IDIVAL’s European Project Officer, presents the SAM project at the Government of Cantabria alongside the Regional Minister of Economy, Finance, Autonomous Financing and European Funds, Luis Ángel Agüeros.

The solution incorporates computer vision to support the clinical assessment of a condition affecting nearly 500 people in Cantabria.

The Marqués de Valdecilla Research Institute (IDIVAL), the University of Cantabria (UC) and Viacore IT have developed an innovative application that facilitates the treatment of diabetic foot for healthcare professionals without specialized podiatry training. Thanks to computer vision, this solution generates digital images for the design of temporary insoles required to treat this condition — a significant step forward in preventing and managing a disorder that, according to the latest data from Primary Care, affects 477 people in the region.

In Cantabria, there are 35,352 people over the age of 18 living with type 2 diabetes. According to the Spanish National Health System’s Diabetes Strategy, 30% of them have a “foot at risk”. This condition, driven by a combination of circulatory problems and diabetic neuropathy, is characterized by the appearance of ulcers and infections that often precede an amputation. In fact, according to the Spanish National Consensus Conference on Lower Extremity Ulcers (CONUEI), amputations occur in between 14% and 20% of these cases.

However, up to 85% of problems associated with diabetic foot can be prevented through a combination of care and health education. Early diagnosis, preventive measures and appropriate treatment are essential to preserve foot health and avoid a significant number of amputations.

Although Cantabria was the first region in Spain to include podiatry services within its public healthcare system, the lack of specialists in the National Health System means that most patients are treated primarily by Primary Care professionals.

The drive of nurse Raquel Sarabia, a member of IDIVAL’s Nursing Research Group and a lecturer at the University of Cantabria, has been key to ensuring the success of this research project. Funded through various competitive calls published by IDIVAL, her work — together with the involvement of other Primary Care nurses — has led to the creation of a tool already being successfully used in health centers in Tanos, Sarón and Santillana del Mar.

An app made in Cantabria

Fully developed by Viacore IT, this innovative solution uses computer vision to analyze images of the patient’s foot without requiring specialist podiatry knowledge. It also stores the images in a digital clinical record, helping healthcare professionals to monitor patients’ progress and compare the evolution of lesions in a structured way.

The program captures graphic resources using an electronic device (tablet or smartphone) and automatically detects both the foot’s outline and high-pressure areas with precision. From there, it analyzes the information to anticipate the need for insoles — technically referred to as pressure offloading — as well as potential lesions at an early stage. These features make it possible to design and implement highly personalized treatments that are more effective, promoting wound healing and reducing the risk of ulceration.

The software has been designed primarily for Primary Care nursing staff, though it is also useful for podiatrists, family doctors and other healthcare professionals. Its cloud-based architecture ensures it can be used by multiple users simultaneously without performance issues. In addition, it can be integrated with Single Sign-On systems, improving interoperability with other healthcare platforms.

Although it has so far only been piloted within the Cantabrian Health Service, the application has been designed for easy integration into any large-scale healthcare system. It’s also worth noting its potential for research, as it generates a significant volume of data that could be used to improve prevention and treatment protocols.

What exactly is diabetic foot?

Diabetic foot is one of the most serious complications of diabetes, characterized by the appearance of ulcers and infections. If not properly managed, it can lead to amputation. The condition results from a combination of circulatory problems linked to diabetes and diabetic neuropathy. This nerve damage causes a loss of sensation in the feet, meaning patients may not feel wounds or abnormal pressure. Together, these factors lead to poor wound healing and an increased risk of infections.

Effective offloading — relieving pressure on the foot while protecting healing tissue — is essential for treating diabetic foot ulcers. This involves redistributing weight and reducing both vertical and shear forces to prevent further damage in the affected area.

Photo caption: From left to right, Paloma González, Innovation Support Technician and Project Manager at IDIVAL; David Pérez, Business Development Director at Viacore IT; and Mónica Cueli, nurse at the Tanos Health Center, Cantabrian Health Service, and member of IDIVAL. In the text, an image of the app, and in the gallery at the end, a summary of the presentation event.

The Marqués de Valdecilla Research Institute (IDIVAL) has successfully passed its annual certification audit, held on April 9th and 10th, reaffirming its commitment to the highest standards of quality and innovation. The external evaluation has renewed the institute’s certification under the UNE 166.002:2021 standard, relating to R&D&I Management, and the UNE-EN ISO 9001:2015 standard, a global benchmark for Quality Management Systems.

The audit, conducted by an independent entity, focused specifically on two of IDIVAL’s key structures: the Valdecilla Biobank and the Innovation Support Unit.

Benchmark Standards: A Guarantee of Excellence
The UNE 166.002:2021 standard establishes the requirements for designing, implementing, maintaining, and improving an R&D&I Management System. Its aim is to help organizations promote research and innovation in a structured, systematic, and sustainable way, ensuring that innovative ideas are effectively managed from conception to application and market transfer.

Meanwhile, the UNE-EN ISO 9001:2015 standard certifies the existence of a robust Quality Management System, focused on customer satisfaction and continuous process improvement.

Valdecilla Biobank: Driving Biomedical Research
The Valdecilla Biobank has once again demonstrated its commitment to continuous improvement, consolidating its position as a strategic infrastructure for biomedical research in Cantabria. This resource provides researchers with access to high-quality biological samples and associated clinical data, under strict ethical and legal standards. The certification endorses excellence across all Biobank processes, from sample collection and processing to storage and allocation for scientific projects.

Compliance with the ISO 9001 standard in the Biobank ensures that every procedure is standardized and controlled, guaranteeing sample traceability and reliability — critical factors for scientific progress.

Innovation Support Unit: A Comprehensive Ecosystem to Drive R&D&I in Healthcare
IDIVAL’s Innovation Support Unit has been recognized for its strategic management of innovation and its fundamental role in knowledge transfer within the healthcare sector. The unit offers a comprehensive range of services covering all stages of the innovation process:

• Identification, development, and support of innovative ideas, accompanying healthcare professionals and researchers from the earliest stages through to the valorization of results.

• Management of industrial and intellectual property, including the protection of inventions through patents and intellectual property registrations.

• Promotion of technology transfer and the creation of technology-based companies (spin-offs).

• Fostering of an innovation culture through training programs, awareness initiatives, and idea contests.

• Encouragement of public-private collaboration, facilitating connections between the healthcare system and the business sector.

• Support for the valorization and development of projects through strategic partnerships.

In addition, the Innovation Support Unit stands out for two particularly strategic areas of activity:

Usability Evaluation
IDIVAL provides usability evaluation services for healthcare products and solutions, conducting thorough analyses through interaction tests with end users (professionals and patients). These evaluations help optimize the design, functionality, and safety of new devices, applications, or processes, ensuring they truly meet the needs of the healthcare environment.

The methodologies applied include field studies, heuristic tests, interviews, and other advanced techniques that help identify improvement areas and increase the chances of successful innovation adoption.

Development of Prototypes and Innovative Solutions
The unit also facilitates the development of functional prototypes for innovations emerging from clinical and research settings. Through its prototyping program, IDIVAL helps transform ideas into initial products or solutions that can be validated in real-world settings.

This support is key for maturing technologies at early stages, increasing their value, validating their clinical usefulness, and improving their market transfer or healthcare system implementation opportunities.

Digital Support Tools
A standout element is the use of Fundanet Innova, a digital platform developed with IDIVAL’s participation, which allows comprehensive management of the innovation lifecycle: from idea collection and feasibility analysis to development, transfer, and follow-up.

Thanks to this comprehensive strategy, IDIVAL makes a decisive contribution to strengthening Cantabria’s healthcare innovation ecosystem, promoting solutions that improve clinical practice and directly benefit patients.

A Strategic Commitment to Quality and Innovation
The renewal of these certifications not only demonstrates compliance with regulatory requirements but also highlights IDIVAL’s firm commitment to integrating quality, innovation, and continuous improvement as strategic pillars of its activity.

This track record consolidates IDIVAL as a national benchmark in biomedical research and healthcare innovation, fostering an environment where science and technology translate into tangible benefits for society.

A team of researchers from the Valdecilla Research Institute (IDIVAL) and the University of Cantabria has developed a targeted nanomedicine capable of selectively delivering chemotherapy to tumors, avoiding toxic effects on healthy tissues. The study, which reports promising preclinical results, has been published in the prestigious journal Small.

The Nanomedicine Group at IDIVAL and the University of Cantabria has achieved a pioneering breakthrough in the treatment of malignant melanoma through the development of a highly precise therapeutic strategy based on silica nanoparticles. This innovative system allows the encapsulation and targeted delivery of anticancer drugs, releasing and activating them in a controlled manner within the tumor to prevent side effects.

The study, published in the international journal Small, was made possible thanks to patented technology developed by IDIVAL researchers for the encapsulation of nucleic acids in nanoparticles. It also involved the collaboration of the Nucleic Acid Chemistry Group at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC).

In this research, an oligonucleotide designed as an intelligent prodrug has been encapsulated, capable of releasing up to ten molecules of the potent chemotherapeutic agent 5-fluorouracil (5-FU) per oligonucleotide unit. This approach overcomes one of the main limitations of conventional 5-FU use: its rapid degradation in the body and the side effects associated with systemic administration.

Thanks to the coating of the nanoparticles with specific proteins, the researchers successfully directed them selectively toward the blood vessels feeding the tumor. Results obtained in mouse models of malignant melanoma are conclusive, achieving up to a 50% reduction in tumor size after just three intravenous treatments.

This work opens new possibilities for the development of more effective, personalized, and less toxic cancer therapies. The recent licensing of the silica encapsulation technology to Iridia Inc. for encrypted DNA-based analog data storage applications not only highlights its potential in this area but also underscores its versatility and disruptive nature in other fields.

The project has received financial support from the Instituto de Salud Carlos III through projects PI22/00030 and DTS24/00023.

IDIVAL has shown clear interest in exploring the biological applications of the patent and is actively seeking to establish a strategic partnership to advance the development of biomedical applications.

Reference:
Targeted Tumor Microenvironment Delivery of Floxuridine Prodrug via Soluble Silica Nanoparticles in Malignant Melanoma as a Model for Aggressive Cancer Treatment
A Ramos-Valle, A Domínguez, N Navarro, A Márquez López, A Avino, R Eritja, C Fabrega, L García-Hevia, ML Fanarraga
Small, DOI: 10.1002/smll.202407752

Link to the article: https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202407752

Image caption: Nanomedicine Laboratory at IDIVAL

Cantabria’s Most Important Healthcare Event Will Take Place on June 10–11 at Espacio Comillas, Universidad de Comillas

On June 10 and 11, 2025, Universidad de Comillas will become the epicenter of healthcare debate and innovation in Cantabria with the celebration of the 15th Patient Safety and Quality Conference, which this year will be held alongside the 1st Regional Health Congress.

The event, organized by the Regional Ministry of Health and the Cantabrian Health Service through the Sub-Directorate for Care, Training, and Continuity of Care, will bring together healthcare professionals from all fields in a forum designed to share knowledge, highlight best practices, and create synergies that contribute to the continuous improvement of the healthcare system.

A Space for Innovation, Dialogue, and Leadership

Espacio Comillas, an emblematic and modern venue, will host this event designed to foster a participatory environment in which essential topics will be addressed, such as innovation in care and healthcare processes, patient safety, regional healthcare leadership, and digital transformation in healthcare.

In addition, professionals are encouraged to take an active role by submitting oral communications and poster presentations, which will have their own dedicated space within the program. Key dates for submitting contributions are now open:

• May 5: Deadline for abstract submissions.

• June 4: Deadline for submitting posters and graphic presentations.

Clear, Strategic Goals

The Conference and Congress will focus on four major objectives:

• Foster innovation and the exchange of healthcare experiences.

• Promote safe and high-quality clinical practices.

• Position Cantabria as a regional healthcare benchmark.

• Drive digital transformation and health and social care coordination.

The organizers anticipate a strong turnout and aim to make this event a key meeting point for the region’s healthcare sector.

Free Transportation for Attendees

To facilitate attendance, free shuttle buses will be available from Cantabria’s main hospitals:

• Hospital de Laredo

• Hospital General Sierrallana-Tres Mares

• Hospital Universitario Marqués de Valdecilla

Seats are limited and must be booked through the registration section.

All information regarding registration, abstract submission, and logistics is available on the official congress website: https://www.scsalud.es/i-congreso-regional-de-salud

See you in Comillas!

The Marqués de Valdecilla University Hospital (HUMV) and the IDIVAL Health Research Institute are advancing in the multicenter clinical trial CASSANDRA, which evaluates in humans the experimental drug IDP-121, a direct cMyc inhibitor — a key protein involved in the development of most cancers.

This phase I/II study is aimed at patients with Multiple Myeloma, high-grade Non-Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia, with the goal of determining the safety, tolerability, and preliminary clinical activity of this compound.

The trial is coordinated by Dr. Enrique M. Ocio, Head of the Hematology Department at HUMV and leader of the Hematology and Hemotherapy Group at IDIVAL. To date, seven patients have been enrolled in the dose-escalation phase, with no significant toxicities reported. Despite the low doses administered, a certain antitumor effect has been observed in some patients, achieving disease stabilization.

In parallel, complementary biological studies are being conducted at Valdecilla, coordinated by Dr. Santiago Montes, aiming to identify the mechanisms responsible for IDP-121’s activity and to better understand its molecular impact on these types of malignancies.

The CASSANDRA trial is being carried out in collaboration with four other Spanish hospitals: Vall d’Hebron Hospital (Barcelona), 12 de Octubre University Hospital (Madrid), University Hospital of Salamanca, and Virgen de la Arrixaca Clinical Hospital (Murcia).

This study represents a search for new therapeutic alternatives in hematologic oncology, particularly in diseases with limited options after multiple lines of treatment.

More information about the IDP-121-001 (CASSANDRA) clinical trial is available at clinicaltrials.gov (Identifier: NCT05908409).

The research, conducted by professionals from the Marqués de Valdecilla University Hospital and researchers from the IDIVAL Health Research Institute, evaluates the usefulness of the GAP index as a prognostic marker in patients with interstitial lung diseases referred for transplantation.

Researchers from the Marqués de Valdecilla Research Institute (IDIVAL), in collaboration with the Pulmonology Department at Marqués de Valdecilla University Hospital, have published a new study in the journal Clinical Transplantation exploring the value of the GAP index as a tool to support decision-making in patients with interstitial lung diseases (ILD) who are candidates for lung transplantation.

The study was led by the Lung Transplant Unit team at the hospital, which has over 28 years of experience and serves as the national reference center (CSUR) for the northern region of Spain (Asturias, Cantabria, the Basque Country, La Rioja, Navarre, and northern Castilla y León). It is also part of the European Reference Network for Rare Respiratory Diseases (ERN-Lung) and has held ISO 9001 quality certification since 2013.

A clinical challenge: identifying patients in time

Interstitial lung diseases have become the leading indication for lung transplantation, both in Spain and internationally. However, their progression is unpredictable: some patients deteriorate slowly, while others worsen within months. This makes management difficult and puts the lives of patients who are not referred to specialized units in time at risk.

Previous studies by the same team had already shown that delayed referral reduces the chances of being included on the transplant waiting list. For this reason, the Valdecilla unit has actively worked to raise awareness among other hospitals of the importance of early referral for these patients, in line with the recommendations of the International Society for Heart and Lung Transplantation (ISHLT).

GAP: a simple tool with clinical potential

Unlike other pulmonary diseases, such as COPD or pulmonary hypertension, interstitial lung diseases do not have a prognostic scoring system recognized by the ISHLT to guide listing for transplantation. In this context, the researchers decided to assess the usefulness of the GAP index — based on gender, age, and two pulmonary function tests (FVC and DLCO) — as a prognostic tool in patients already diagnosed with ILD and referred for transplantation.

This index, originally developed for newly diagnosed Idiopathic Pulmonary Fibrosis patients, was applied for the first time in this study to a cohort of prevalent patients with any type of interstitial lung disease. The results showed that the GAP index also allows for adequate prognostic stratification in these patients, even at the time of their first consultation in the transplant unit.

A first step toward a change in clinical practice

Although this is a single-center study, its authors believe it could have significant clinical value. The use of simple, accessible tools such as the GAP index could help better identify patients with poorer prognoses, allowing for prioritized inclusion on the transplant waiting list and thereby increasing their chances of survival.

The Valdecilla team encourages other centers to validate these findings and continue working on strategies to optimize referral times and access to transplantation for this type of patient.

Link to the article: https://onlinelibrary.wiley.com/doi/10.1111/ctr.70136

Photo caption: Professionals from the Lung Transplant Unit and the Pulmonology Department at HUMV

This Sunday, April 27, the Municipal Stadium of Los Corrales de Buelna will host one of Cantabria’s largest solidarity events: the 15th edition of “Luchamos por la vida” (“We Fight for Life”). Every year, this initiative brings together sports, social commitment, and support for scientific research — and this time, it returns with an ambitious goal: to break the Guinness World Record for the largest human pink ribbon, surpassing the current record of 8,264 people.

The event will kick off at 10:30 a.m. and will feature activities for all ages: children’s workshops, sports exhibitions, raffles, music, and the much-anticipated solidarity walk, which this year will be launched by footballer David Villa. In addition to aiming for a historic show of unity in the fight against cancer, the event has a strong research focus: all proceeds go to support scientific projects targeting this disease.

This year, the organizers will donate €20,000 to a project developed by the Melatonin and Breast Cancer Research Group at the Marqués de Valdecilla Research Institute (IDIVAL), led by Dr. Virginia Álvarez García and Dr. Carlos Sainz Fernández. Their study addresses one of the most pressing challenges in modern oncology: understanding how aggressive breast tumors — such as triple-negative and HER2+ — develop resistance to treatments like chemotherapy and radiotherapy.

The research team is analyzing the role of a key protein, PKCϴ, in the DNA repair mechanisms that enable tumor cells to survive treatment-induced damage. Understanding these processes could lead to new therapeutic approaches that block the tumor’s ability to recover, increasing the effectiveness of current treatments and lowering the risk of relapse.

At IDIVAL, we would like to express our deepest gratitude to the “Luchamos por la vida” organization and everyone taking part for their commitment to science and health. Events like this one show that biomedical research is a cause that unites us all — and that every step (or every race bib) counts in the fight against cancer.

Would you like to be part of this historic and meaningful challenge?
There’s still time to sign up for just €3, which will go entirely to support cancer research. Click here to register

See you this Sunday in Los Corrales de Buelna!

A team from the Immunopathology Group at IDIVAL, the University of Cantabria, and the Cantabrian Health Service has discovered a relationship between bone metabolism and vulnerability to SARS-CoV-2.

The study, led by Drs. Emilio Pariente and José Luis Hernández, was recently published in the scientific journal Current Medical Research and Opinion and sheds light on a rarely explored aspect of the pandemic: Could an imbalance in bone metabolism make us more prone to developing COVID-19?

To answer this question, the researchers defined a new index of altered bone metabolism (AOMI), which integrates key markers of bone formation, degradation, quality, and quantity. Applying this index to more than 800 participants from the Camargo Cohort, the team found that individuals with altered bone metabolism (AOMI+) had a significantly higher risk of SARS-CoV-2 infection. Remarkably, this risk remained even after adjusting for factors such as age, sex, or the presence of other diseases.

The findings point to a complex scenario, involving persistent systemic inflammation, poorer bone quality, and an unfavorable lipid profile — that is, an altered balance of cholesterol and other fats in the blood. Moreover, the link between bone metabolism and coronavirus infection was especially strong in younger individuals, suggesting that hormonal mechanisms may also be involved.

Another key finding is that bone quality — measured through the so-called trabecular bone score (TBS) — appeared to be more relevant than bone quantity (bone mineral density) in predicting the risk of infection.

An Underexplored Link Between Immunity and Bone Metabolism

This study opens a new line of research in the field of immuno-osteology, a discipline that investigates how the immune system and the skeletal system interact. According to the authors, bone biomarkers could become indirect indicators of infection vulnerability in the future, and even help identify at-risk populations in the context of new pandemics.

The research was made possible through the collaborative efforts of a multidisciplinary team, including researchers from IDIVAL’s Immunopathology Group, professionals from the Internal Medicine and Rheumatology departments at Marqués de Valdecilla University Hospital, faculty from the University of Cantabria’s School of Medicine, and primary care physicians from the Camargo and Solares health centers. Among the authors are Emilio Pariente, Marta Martín, Daniel Nan, Daniel Martínez, Héctor Basterrechea, Javier Pardo, Merelyn Bonome, Sandra Solares, Carmen Ramos, José Manuel Olmos, Raquel Pascua, Víctor M. Martínez, and José Luis Hernández.

📄 You can read the full article on PubMed: https://pubmed.ncbi.nlm.nih.gov/40094222/

Photo caption: From left to right, Dr. Emilio Pariente, family physician in Camargo and associate professor at the University of Cantabria; Dr. José Manuel Olmos, co-PI of the Camargo Cohort and Professor of Medicine at UC; and Dr. José Luis Hernández, PI of the Camargo Cohort, Head of Internal Medicine at HUMV, and associate professor at UC. All three are members of the Immunopathology Group at IDIVAL.